Safety and Tolerability of the Dual 5-Alpha Reductase Inhibitor Dutasteride in the Treatment of Androgenetic Alopecia
2
조회
0
다운로드
2
인용
0
참고문헌
키워드
초록
Background: After the approval of dutastride for androgenic alopecia (AGA) in 2009, Korean authority required a post-marketing surveillance to obtain further data on its safety profile. Objective: The objective was to monitor adverse events (AEs) of dutasteride 0.5 mg in Korean AGA male patients in a clinical practice environment. Methods: Open label, multi-center, non-interventional observational study was done from July 2009 to July 2013. AGA subjects (18∼41 years of age) with no experience of dutasteride were enrolled. Dosage regimen was recommended according to the prescribing information. The incidences of any AEs, serious adverse events (SAEs), and adverse drug reactions (ADRs) were evaluated. Multiple logistic regression method was used to identify risk factors related to ADRs. Effectiveness was generally evaluated by physicians. Results: During study period, 712 subjects were enrolled. The subjects of 29.3±6.0 years old exposed to dutasteride for 204.7±161.5 days. One hundred and ten (15.4%) of subjects reported 138 AEs. Four subjects (0.6%) reported 5 SAEs (right radius fracture, 2 events of chronic follicular tonsillitis, influenza infection, and acute appendicitis). Sixty-six subjects (9.3%) reported 80 ADRs. Most frequent ADRs were libido decreased (9 subjects, 1.3%), dyspepsia (8 subjects, 1.1%), impotence (7 subjects, 1.0%), and fatigue (5 subjects, 0.7%). Other interested ADRs were sexual function abnormality (4 subjects, 0.6%), gynecomastia (2 subjects, 0.3%), and ejaculation disorder (1 subject, 0.1%). Most subjects (78.6%) showed overall improvement after treatment of dutasteride in the effectiveness. Conclusion: Dutasteride 0.5 mg is to be well-tolerated in 18 to 41 years old AGA patients in a clinical practice environment.
Abstract
Background: After the approval of dutastride for androgenic alopecia (AGA) in 2009, Korean authority required a post-marketing surveillance to obtain further data on its safety profile. Objective: The objective was to monitor adverse events (AEs) of dutasteride 0.5 mg in Korean AGA male patients in a clinical practice environment. Methods: Open label, multi-center, non-interventional observational study was done from July 2009 to July 2013. AGA subjects (18∼41 years of age) with no experience of dutasteride were enrolled. Dosage regimen was recommended according to the prescribing information. The incidences of any AEs, serious adverse events (SAEs), and adverse drug reactions (ADRs) were evaluated. Multiple logistic regression method was used to identify risk factors related to ADRs. Effectiveness was generally evaluated by physicians. Results: During study period, 712 subjects were enrolled. The subjects of 29.3±6.0 years old exposed to dutasteride for 204.7±161.5 days. One hundred and ten (15.4%) of subjects reported 138 AEs. Four subjects (0.6%) reported 5 SAEs (right radius fracture, 2 events of chronic follicular tonsillitis, influenza infection, and acute appendicitis). Sixty-six subjects (9.3%) reported 80 ADRs. Most frequent ADRs were libido decreased (9 subjects, 1.3%), dyspepsia (8 subjects, 1.1%), impotence (7 subjects, 1.0%), and fatigue (5 subjects, 0.7%). Other interested ADRs were sexual function abnormality (4 subjects, 0.6%), gynecomastia (2 subjects, 0.3%), and ejaculation disorder (1 subject, 0.1%). Most subjects (78.6%) showed overall improvement after treatment of dutasteride in the effectiveness. Conclusion: Dutasteride 0.5 mg is to be well-tolerated in 18 to 41 years old AGA patients in a clinical practice environment.
참고문헌 (19)
- DeMuro-Mercon C., "Male-pattern hair loss in Norwegian men : a community-based study", Dermatology, 200, pp.219~222 (2000)
- Takashima M., "Hair research status and future aspects", pp.287~293 (1981), Springer-Verlag
- Paik JH., "The prevalence and types of androgenetic alopecia in Korean men and women", Br J Dermatol, 145, pp.95~99 (2001)
- Su LH., "Association of androgenetic alopecia with smoking and its prevalence among Asian men : a community-based survey", Arch Dermatol, 143, pp.1401~1406 (2007)
- Xu F., "Prevalence and types of androgenetic alopecia in Shanghai, China : a community-based study", Br J Dermatol, 160, pp.629~632 (2009)
- 장우선, "The Annual Changes of Clinical Manifestation of Androgenetic Alopecia Clinic in Korean Males and Females: A Outpatient-Based Study", Annals of Dermatology, 25(2), pp.181~188 (2013), 대한피부과학회
- Ellis JA., "Mal. pattern baldness: current treatments, future prospects", Drug Discov Today, 13, pp.791~797 (2008)
- 최광성, "한국인의 두피모발 특성과 남성형탈모증", 대한의사협회지, 56(1), pp.45~54 (2013), 대한의사협회
- Eun HC., "Efficacy, safety, and tolerability of dutasteride0.5 mg once daily in mal. patients with mal. pattern hair loss: a randomized, double-blind, placebo-controlled, phase III study", J Am Acad Dermatol, 63, pp.252~258 (2010)
- Gubelin Harcha W., "A randomized, active- and placebo-controlled study of the efficacy and safety of different doses of dutasteride versus placebo and finasteride in the treatment of mal. subjects with androgenetic alopecia", J Am Acad Dermatol, 70, pp.489.e3~498.e3 (2014)
- Olsen EA., "The importance of dual 5alpha-reductase inhibition in the treatment of mal. pattern hair loss: results of a randomized placebo-controlled study of dutasteride versus finasteride", J Am Acad Dermatol, 55, pp.1014~1023 (2006)
- "Guideline for Korean New Drug Re-Examination" (2012)[URL]
- Wilson JD., "Steroid 5 alpha-reductase 2 deficiency", Endocr Rev, 14, pp.577~593 (1993)
- Kaufman KD., "Finasteride in the treatment of men with androgenetic alopecia", J Am Acad Dermatol, 39, pp.578~589 (1998)
- Thiboutot D., "Activity of the type 1 5 alpha-reductase exhibits regional differences in isolated sebaceous glands and whole skin", J Invest Dermatol, 105, pp.209~214 (1995)
- Eicheler W., "Immunocytochemical localization of human 5 alpha-reductase 2 with polyclonal antibodies in androgen target and non-target human tissues", J Histochem Cytochem, 42, pp.667~675 (1994)
- Thigpen AE., "Tissue distribution and ontogeny of steroid 5 alpha-reductase isozyme expression", J Clin Invest, 92, pp.903~910 (1993)
- Drake L., "The effects of finasteride on scal. skin and serum androgen levels in men with androgenetic alopecia", J Am Acad Dermatol, 41, pp.550~554 (1999)
- Debruyne F., "Efficacy and safety of long-term treatment with the dual 5 alpha-reductase inhibitor dutasteride in men with symptomatic benign prostatic hyperplasia", Eur Urol, 46, pp.488~494 (2004)